Current Opportunities in Health Sector

Here are a list of the current opportunities available for #SMEs in the region. For regular updates, subscribe to our weekly mailing list (email

BBSRC-DEFRA global coronavirus research and innovation network

Apply for £500,000 to establish a single international network for research into coronaviruses. The network may run for up to four years.

You must be of lecturer level (or equivalent) and based at an eligible UK research organisation.

Your proposal should seek to coordinate research in the following areas:

  • pathogen biology (including the seasonality, transmission, ecology and evolution of coronaviruses)
  • host response
  • effective intervention strategies.

Deadline 23 February 2021.

Learn more here.

Smart Grant: November 2020

Opportunity for UK registered organisations to apply for a share of up to £25 million from Innovate UK to deliver disruptive R&D innovations that can significantly impact the UK economy.

Deadline 20th January.

Read more here.

Asthma health technology

Deadline: 11 February 2021

Up to £750,000 is available to support research and development of technologies for diagnosis, monitoring and management tools for asthma. 

Read more here.

Joint Global Health Trials

Deadline: 4 February 2021

Trial development applications are typically up to £200k and 2 years duration and should aim to improve health in low- and middle-income countries (LMICs). 

Read more here.

Deadline 4th February.

Biomedical Catalyst: Developmental Pathway Funding Scheme (DPFS)

Deadline: 24th March 2021

Supports the translation of fundamental discoveries toward benefits to human health. Funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies.

Supports academically led projects whose goals are to improve prevention, diagnosis, prognosis, or treatment of significant health needs, or that focus on developing research tools that increase the efficiency of developing interventions.

The following activities are eligible for support

  • Developing candidate therapeutic entities (e.g. drug discovery)
  • Pre-clinical testing of novel therapeutic entities
  • Early-phase clinical studies of novel therapeutic entities (phases 1 and 2)
  • “Repurposing” clinical studies – using existing therapies for new indications
  • Developing and testing novel devices
  • Developing and testing diagnostics (including biomarker validation)